5IU.F ISOFOL MEDICAL AB

Healthcare Biotechnology Frankfurt Exchange
0.1100 EUR
Close of Nov 11, 2026
0.0398 0.1308
Market cap
EUR 35.3M
P/E
-
P/B
4.39x
ROE
-64.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5IU.F undervalued?

Graham number

The Graham number of ISOFOL MEDICAL AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ISOFOL MEDICAL AB fundamental analysis

No fundamental analysis for ISOFOL MEDICAL AB yet.

ISOFOL MEDICAL AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ISOFOL MEDICAL AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.

Full company profile